GILD
NASDAQ · Biotechnology
Gilead Sciences Inc
$138.36
+0.22 (+0.16%)
GILD News12 articles
XLV Retreats from Record as Mid-Sized Health Care Names Lag
XLV hit a record $169.71 before closing lower, lagging the S&P 500 by 0.74 points. Weakness among smaller health care holdings offset gains in top components.
Amgen Lifts 2026 Forecast as Five Growth Brands Offset $772M Slump
Amgen (AMGN) raised its 2026 guidance after Q2 revenue beat estimates, as five growth brands added $923M in sales, offsetting a $772M decline from five struggling products.
Vertex Raises Outlook as CF Dominates, Non-CF Push Faces Steep Climb
Vertex Pharmaceuticals raised its 2026 outlook after strong Q2, but non-CF drugs Casgevy and Journavx face a 53% H2 growth hurdle.
TrumpRx Expansion to 800+ Drugs Heightens Tariff Risk for Generic Makers
Generic drug stocks fell after Trump announced tariffs up to 200% on imports by 2029, as TrumpRx expands to over 800 medications with 79 brand deals.
TrumpRx Program Shows Limited Big Pharma Impact
TrumpRx's 79 presidential deals cover just 10% of branded drugs from 17 pharma firms, far below the touted 800. Major drugs like Ibrance and Biktarvy are excluded, limiting investor risk.
Healthcare Earnings Test: J&J, UnitedHealth, Abbott in Focus After Sector's 9% Drop
Major healthcare stocks report this week as the sector's 9% earnings decline goes under the microscope. J&J, UnitedHealth, and Abbott are key to determining if the drop is real or just a one-off.
Merck Shares Jump as New Drug Data Eases Keytruda Concerns
Merck shares surged 4.9% to $120.26 after ASCO data showed its new cancer drug sac-TMT combined with Keytruda improved progression-free survival, reinforcing confidence in the post-Keytruda pipeline.
Tempus AI Faces Pivotal May with Q1 Results and Inaugural Investor Day
Tempus AI reports Q1 results May 5 and holds its first investor day May 29, with Merck CEO highlighting the partnership. Stock trades near $55.44 with a $9.7B market cap.
Gilead Shares Dip as Yeztugo Sales Outlook Disappoints
Gilead Sciences shares declined as its 2026 sales projection for the HIV prevention drug Yeztugo fell short of some Wall Street estimates. Several brokerages raised price targets following the company's earnings report.
Eli Lilly shares retreat as $2.4B Orna acquisition and China partnership draw scrutiny
Eli Lilly's stock declined 0.9% as investors assessed the company's strategic moves into cell therapy and Chinese drug development. The market is weighing increased pipeline spending against intensifying competition in obesity treatments.
Eli Lilly Shares Dip Following $2.4 Billion Orna Therapeutics Acquisition Announcement
Eli Lilly shares declined 1.3% in after-hours trading after announcing a $2.4 billion acquisition of Orna Therapeutics. Investors are monitoring the deal's impact on Lilly's pipeline and upcoming regulatory decisions.
Gilead Hits 52-Week Peak on FDA Label Expansion for Yescarta, Earnings in Focus
Gilead Sciences reached a 52-week high after the FDA approved a label update for its Yescarta therapy, expanding use to a rare brain lymphoma. The stock's rally comes ahead of the company's quarterly earnings report.